Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Pfizer has taken a beating in recent years, and its market cap is now around $140 billion. But with the company still ...

Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer’s (PFE) experimental MASH therapy ervogastat. Read more here.

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...